newsfilter
← Latest News
PR Newswire·

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and...